FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020828534> ?p ?o ?g. }

• W2020828534 endingPage "52" @default.
• W2020828534 startingPage "45" @default.
• W2020828534 abstract "Etanercept is a recombinant human soluble tumor necrosis factor (TNF-alpha) receptor fusion protein that inhibits TNF-alpha, a major mediator in the pathogenesis of graft-versus-host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 patients with steroid-refractory acute GVHD (aGVHD) (n = 13) and chronic GVHD (cGVHD) (n = 8). Etanercept 25 mg was given subcutaneously twice weekly for 4 weeks followed by 25 mg weekly for 4 weeks. At the time of initiation of etanercept, 14 patients had skin, 13 had gastro-intestinal, 5 had liver, 5 had pulmonary, and 4 had oral involvement. Twelve patients (57%) completed 12 doses of therapy. Overall, 11 of 21 patients (52%) responded to the treatment with etanercept, including 6 patients (46%) with aGVHD [n = 4 complete response (CR), n = 2 partial response (PR)] and 5 patients (62%) with cGVHD (n = 1 CR, n = 4 PR). Clinical responses were most commonly seen in patients with refractory gut aGVHD with 55% of the patients having a CR and 9% having a PR. CMV reactivation occurred in 48% of patients, bacterial infections in 14% of patients, and fungal infections in 19% of patients. Fourteen patients (67%) were alive after a median follow-up of 429 days (range 71-1007 days) since initiation of etanercept. Seven patients died, 3 of infections, 2 of refractory aGVHD, and 2 of disease progression. In conclusion, our preliminary data indicate that etanercept is well tolerated and can induce a high response rate in patients with steroid-refractory aGVHD and cGVHD, particularly in the setting of GI involvement." @default.
• W2020828534 created "2016-06-24" @default.
• W2020828534 creator A5012551804 @default.
• W2020828534 creator A5022712318 @default.
• W2020828534 creator A5039326163 @default.
• W2020828534 creator A5040794664 @default.
• W2020828534 creator A5058253118 @default.
• W2020828534 date "2006-08-25" @default.
• W2020828534 modified "2023-10-17" @default.
• W2020828534 title "Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation" @default.
• W2020828534 cites W1500757144 @default.
• W2020828534 cites W1530764705 @default.
• W2020828534 cites W1539774679 @default.
• W2020828534 cites W1969194297 @default.
• W2020828534 cites W1984164701 @default.
• W2020828534 cites W2006447742 @default.
• W2020828534 cites W2011578371 @default.
• W2020828534 cites W2016413269 @default.
• W2020828534 cites W2024402262 @default.
• W2020828534 cites W2053278212 @default.
• W2020828534 cites W2065419624 @default.
• W2020828534 cites W2076326759 @default.
• W2020828534 cites W2079044693 @default.
• W2020828534 cites W2082007625 @default.
• W2020828534 cites W2091135137 @default.
• W2020828534 cites W2094292853 @default.
• W2020828534 cites W2109168421 @default.
• W2020828534 cites W2116128754 @default.
• W2020828534 cites W2143436585 @default.
• W2020828534 cites W2151755269 @default.
• W2020828534 cites W2165524100 @default.
• W2020828534 cites W2166247768 @default.
• W2020828534 cites W2168155959 @default.
• W2020828534 cites W2169004170 @default.
• W2020828534 cites W2328305239 @default.
• W2020828534 cites W2618073389 @default.
• W2020828534 doi "https://doi.org/10.1002/ajh.20752" @default.
• W2020828534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16937391" @default.
• W2020828534 hasPublicationYear "2006" @default.
• W2020828534 type Work @default.
• W2020828534 sameAs 2020828534 @default.
• W2020828534 citedByCount "140" @default.
• W2020828534 countsByYear W20208285342012 @default.
• W2020828534 countsByYear W20208285342013 @default.
• W2020828534 countsByYear W20208285342014 @default.
• W2020828534 countsByYear W20208285342015 @default.
• W2020828534 countsByYear W20208285342016 @default.
• W2020828534 countsByYear W20208285342017 @default.
• W2020828534 countsByYear W20208285342018 @default.
• W2020828534 countsByYear W20208285342019 @default.
• W2020828534 countsByYear W20208285342020 @default.
• W2020828534 countsByYear W20208285342021 @default.
• W2020828534 countsByYear W20208285342022 @default.
• W2020828534 countsByYear W20208285342023 @default.
• W2020828534 crossrefType "journal-article" @default.
• W2020828534 hasAuthorship W2020828534A5012551804 @default.
• W2020828534 hasAuthorship W2020828534A5022712318 @default.
• W2020828534 hasAuthorship W2020828534A5039326163 @default.
• W2020828534 hasAuthorship W2020828534A5040794664 @default.
• W2020828534 hasAuthorship W2020828534A5058253118 @default.
• W2020828534 hasBestOaLocation W20208285341 @default.
• W2020828534 hasConcept C126322002 @default.
• W2020828534 hasConcept C142424586 @default.
• W2020828534 hasConcept C17991360 @default.
• W2020828534 hasConcept C203014093 @default.
• W2020828534 hasConcept C2777226972 @default.
• W2020828534 hasConcept C2777408962 @default.
• W2020828534 hasConcept C2779972918 @default.
• W2020828534 hasConcept C2780942790 @default.
• W2020828534 hasConcept C2911091166 @default.
• W2020828534 hasConcept C71924100 @default.
• W2020828534 hasConcept C86803240 @default.
• W2020828534 hasConcept C87355193 @default.
• W2020828534 hasConcept C90924648 @default.
• W2020828534 hasConceptScore W2020828534C126322002 @default.
• W2020828534 hasConceptScore W2020828534C142424586 @default.
• W2020828534 hasConceptScore W2020828534C17991360 @default.
• W2020828534 hasConceptScore W2020828534C203014093 @default.
• W2020828534 hasConceptScore W2020828534C2777226972 @default.
• W2020828534 hasConceptScore W2020828534C2777408962 @default.
• W2020828534 hasConceptScore W2020828534C2779972918 @default.
• W2020828534 hasConceptScore W2020828534C2780942790 @default.
• W2020828534 hasConceptScore W2020828534C2911091166 @default.
• W2020828534 hasConceptScore W2020828534C71924100 @default.
• W2020828534 hasConceptScore W2020828534C86803240 @default.
• W2020828534 hasConceptScore W2020828534C87355193 @default.
• W2020828534 hasConceptScore W2020828534C90924648 @default.
• W2020828534 hasIssue "1" @default.
• W2020828534 hasLocation W20208285341 @default.
• W2020828534 hasLocation W20208285342 @default.
• W2020828534 hasOpenAccess W2020828534 @default.
• W2020828534 hasPrimaryLocation W20208285341 @default.
• W2020828534 hasRelatedWork W2024046618 @default.
• W2020828534 hasRelatedWork W2044696250 @default.
• W2020828534 hasRelatedWork W2126499965 @default.
• W2020828534 hasRelatedWork W2128288007 @default.
• W2020828534 hasRelatedWork W2302449393 @default.
• W2020828534 hasRelatedWork W2416430454 @default.

• next